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ABSTRACT
The molecular characteristics of therapeutically-relevant targets and their 
clinicopathological implications in salivary duct carcinomas (SDCs) are poorly 
understood. We investigated the gene alterations and the immunoexpression of 
crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, 
in order of frequency, were as follows: TP53, 68%; PIK3CA, 18%; H-RAS, 16%; 
BRAF, 4%; and AKT1, 1.5%. PIK3CA/H-RAS/BRAF mutations were more common in 
de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations 
were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were 
frequently detected in cases with the aberrant p53 expression, and TP53 missense 
and truncating mutations were associated with p53-extreme positivity and negativity, 
respectively. DISH analysis revealed no cases of EGFR amplification. The rates of 
PI3K, p-Akt, and p-mTOR positivity were 34%, 22%, and 66%, respectively; PTEN 
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loss was observed in 47% of the cases. These expressions were correlated according 
to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a 
lower expression of androgen receptor. In the multivariate analysis, patients with 
SDC harboring TP53 truncating mutations showed shorter progression-free survival. 
Conversely, p-Akt positivity was associated with a favorable outcome. This study 
might provide information that leads to advances in personized therapy for SDC.
INTRODUCTION
Salivary duct carcinoma (SDC) is an uncommon 
entity, and histologically resembles high-grade mammary 
ductal carcinoma [1]. It occurs as a de novo carcinoma 
(de novo SDC) or a carcinoma ex-pleomorphic adenoma 
(SDC ex-PA) [1]. SDCs are known to be one of the most 
aggressive types of salivary gland carcinoma, since 
patients frequently develop distant metastasis, even 
after curative resection [2, 3]. Surgical resection is the 
standard therapy for SDC; in many cases, postoperative 
radiotherapy is also performed [4]. Although there is no 
established regimen, systemic chemotherapy is often 
carried out in cases with distant metastasis [4, 5].
In the past decade, there have been remarkable 
advances in the research on multiple therapeutically-
relevant genetic alterations in various cancers, and 
appropriate targeted therapies have been generated [6, 
7]. In SDCs, however, there is little data in relation to 
personalized therapy, with the exception of therapies 
targeting HER2 and the androgen receptor (AR); evidence 
for which has gradually accumulated [4, 5]. On the other 
hand, recent studies in which limited comprehensive 
molecular profiling analyses were performed—especially 
those using next-generation sequencing—have revealed 
that several genes are altered in SDCs, including TP53 and 
genes related to cell signaling by receptor-tyrosine kinases, 
the PI3K/Akt pathway, and the RAS-MAPK cascade, 
which play integral roles in tumor growth and the survival 
of various types of carcinoma [8–17]. These studies have 
reported that the percentages of genetic alteration of TP53, 
ERBB2, PIK3CA, and H-RAS, are characteristically high 
in SDC. Although mutations of other key genes, such as 
CDKN2A, PTEN, KIT, and APC also have been described 
in the literature, those frequencies are low, being ≤ 10% 
for any of them [8–17]. Due to the rarity of the SDCs, 
the differences in the genetic mechanisms underlying 
carcinogenesis according to the histologic origin (i.e. de 
novo SDC or SDC ex-PA) [13, 14, 18] and the relationship 
between the aberrant expression of molecular markers and 
the clinical outcome have not been fully explored [8, 9, 
14, 18]. However, it is essential to clarify these issues as 
an initial step in designing effective therapeutic options 
and—in the future—for selecting SDC patients who are 
candidates for targeted therapy. 
The purpose of the present study, the largest cohort 
of SDCs to date, was to determine the gene alteration and 
expression status of selected potentially actionable cancer-
related targets, and to evaluate their clinicopathological 
and prognostic significance in SDC patients.
RESULTS
Patient characteristics
The distribution of the patient characteristics is 
shown in Table 1. The median follow-up period of the 
survivors was 3.7 years (range, 0.4–18.7 years). The 
3-year overall survival (OS) and progression-free survival 
(PFS) rates of the whole study population were 68.5% 
(95% confidence interval [CI]: 60.1–75.5) and 34.3% 
(95% CI: 26.7–42.1), respectively.
Gene alterations and the immunohistochemical 
findings
TP53 mutations were the most frequent genetic 
mutation among all patients with SDC (68%, 85/125 cases), 
followed by the PIK3CA (18%, 25/137 cases), H-RAS (16%, 
23/140 cases), BRAF (3.7%, 5/136 cases), and AKT1 (1.5%, 
2/133 cases) mutations. No K-RAS or N-RAS mutations were 
detected in any of the cases. Twenty-four of the patients 
showed no genetic mutations among the analyzed genes.
TP53 mutations were distributed throughout exons 
4–10, and a subset of TP53-mutated cases simultaneously 
harbored missense, nonsense, and/or frameshift mutations in 
the same or different exons; 23 tumors (18% of the mutated 
tumors) carried more than one TP53 mutation (Supplementary 
Table 1). The percentages of missense (Figure 1A), nonsense, 
and frameshift TP53 mutations (Figure 1B) were 61%, 
9.4%, and 27%, respectively, among the total mutations. 
The frameshift mutations (23 cases) included insertions 
(4 cases), deletions (19 cases) (Figure 1B), and in-frame 
mutations (2 cases). Consequently, the rates of each TP53 
status were as follows: wild-type, 32%; missense mutation, 
42%; and truncating mutation, 26%. PIK3CA mutations 
were detected in either exons 9 (14 cases) or 20 (11 cases) 
(Figure 1C) (Supplementary Table 2). The majority of H-RAS 
mutations were identified in exon 2 (21/23 cases) (Figure 1D) 
(Supplementary Table 2). All of the BRAF mutations were 
represented as a V600E mutation (Figure 1E). In addition, an 
AKT1 mutation was identified as an E17K mutation.
A dual color in situ hybridization (DISH) analysis 
revealed no EGFR gene amplification in any of the cases, 
Oncotarget1854www.impactjournals.com/oncotarget
whereas 14% (19/132 cases) of the cases demonstrated 
chromosome 7 polysomy (Figure 2).
Positive immunoreactivity for PI3K and p-mTOR 
was exclusively observed in the cytoplasm, while p-Akt 
was sometimes detected in the nuclei and cytoplasm by 
immunostaining. The positive rate—in accordance with 
the sequential order of the signaling pathway axis—was 
as follows: PI3K, 34% (51/149 cases) (Figure 3A), p-Akt, 
22% (32/147 cases), nuclear p-Akt, 14% (21/147 cases) 
(Figure 3B), and p-mTOR, 66% (98/149 cases) (Figure 
3C). The loss of PTEN (Figure 3D) was observed in 49% 
of the cases (73/149 cases). 
Mutual relationship between the gene alterations 
and immunohistochemical findings
PIK3CA and H-RAS mutations, which were 
frequently co-mutated (P < 0.001) (Supplementary Table 
2), had a mutually exclusive relationship with the HER2-
positive status (P = 0.004 and < 0.001, respectively) (Table 
2). In contrast, the HER2-positive cases commonly carried 
TP53 mutations (P = 0.044). Meanwhile, TP53 wild-type 
was associated with H-RAS mutations (P = 0.013). Cases 
harboring H-RAS mutations and chromosome 7 polysomy 
showed significantly lower and higher Ki-67 labeling 
index (LI) values, respectively (P = 0.001 and < 0.001, 
respectively). In addition, TP53 and PIK3CA mutations 
tended to have higher and lower Ki-67 LI values, 
respectively (P = 0.057 and 0.069, respectively). 
With regard to the correlation between the TP53-
mutation status and the p53-expression phenotype (Table 
3) (Supplementary Table 1), TP53 mutations were more
frequently identified in p53-extreme negative/positive
cases than in p53-non-extreme cases (P = 0.002).
Moreover, significant correlations were found between
p53-extreme negative and TP53 truncating mutation
Table 1: Patient characteristics (n = 151)
Variables n %
Age (years)
< 65 84 56
 ≥ 65 67 44
Sex
 Male 127 84
 Female 24 16
T classification
 1 13 8
 2 39 26
 3 30 20
 4 69 46
N classification
 0 71 47
 1 9 6
 2 71 47
M classification
 0 142 94
 1 9 6
Primary tumor site
Parotid gland 117 77
Submandibular gland 30 20
 Others 4 3
Histologic origin
De novo 57 38
Ex-pleomorphic adenoma* 89 59
 Unknown 5 3
*Salivary duct carcinomas ex-pleomorphic adenoma (SDCs ex-PA) include 13 intracapsular SDC ex-PA cases, 5 minimally invasive SDC
ex-PA cases, and 71 widely invasive SDC ex-PA cases.
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and between p53-extreme positive and TP53 missense 
mutations (P < 0.001). 
The presence of chromosome 7 polysomy tended 
(with marginal significance [P = 0.065]) to be correlated 
with EGFR overexpression.
The interrelationship between the mutation and 
expression of molecules related to the PI3K/Akt signaling 
pathway is shown in Table 4. PTEN loss was found to be 
connected to PI3K negativity and nuclear p-Akt positivity (P 
= 0.006 and 0.007, respectively). Furthermore, both the overall 
and nuclear p-Akt expression were positively correlated with 
p-mTOR expression (P = 0.032 and 0.034, respectively). On 
the other hand, the PIK3CA status was not associated with the 
expression of PI3K/Akt signaling pathway proteins.
As reported previously, AR immunoreactivity was 
found in 144 of 150 cases (96%) [19]. Besides, PI3K 
(Figure 4A) and p-mTOR negativity, and the loss of PTEN 
(Figure 4B) were associated with a lower AR LI (P = 0.001, 
0.098 [marginal significance], and < 0.001, respectively). 
Correlation between the molecular profile and 
clinicopathologic factors
The significant clinicopathological correlations 
included the presence of PIK3CA gene mutations with 
higher age (P = 0.025), PI3K and p-mTOR positivity 
with an early N classification (P = 0.039 and 0.028, 
respectively), and the loss of PTEN with an advanced T 
classification (P = 0.009).
Of note, the PIK3CA and H-RAS status showed 
significant differences according to the histological origin 
of SDC (Table 5). PIK3CA and H-RAS mutations were 
more commonly identified in de novo SDC than in SDC 
ex-PA (P < 0.001 for each). Similarly, the frequency of 
simultaneous PIK3CA and H-RAS mutations was also 
higher in de novo SDCs (P < 0.001). Even though the 
incidence was low, BRAF mutations were only found 
in de novo SDC. AKT1 mutations were identified in 
one case each of de novo SDC and SDC ex-PA. The 
histological origin was not significantly associated with 
the TP53 mutation status, chromosome 7 polysomy, or the 
expression of PI3K, p-Akt, p-mTOR, and PTEN.
Prognostic impact
The data of the univariate and multivariate 
Cox proportional hazard analyses of the molecular 
and immunohistochemical variables associated with 
survival are summarized in Table 6. The univariate 
analysis revealed that patients with TP53 mutated 
Table 2: Mutual correlation between gene alterations and immunohistochemical findings in 
salivary duct carcinomas
 –
TP53 PIK3CA H-RAS BRAF
WT Mut P WT Mut P WT Mut P WT Mut P
HER2  – –  – –  – –  – –  – –  – –
   Neg 27 41
0.044*
54 20
0.004*
53 22
< 0.001*
69 5
0.037*
   Pos 13 44 58 5 64 1 62 0
 – –  – –  – –  – –  – –  – –
TP53  – –  – –  – –  – –  – –  – –
 WT  – –  – 32 8
N.S.
28 12
0.013*
37 3
N.S.
  Mut  – –  – 71 14 75 10 82 2
 – –  – –  – –  – –  – –  – –
PIK3CA  – –  – –  – –  – –  – –  – –
 WT  – –  – –  – – 103 9
< 0.001*
108 3
N.S.
  Mut  – –  – –  – – 11 14 22 2
 – –  – –  – –  – –  – –  – –
H-RAS  – –  – –  – –  – –  – –  – –
 WT  – –  – –  – –  – –  – 108 5
N.S.
Mut  – –  – –  – –  – –  – 23 0
 – –  – –  – –  – –  – –  – –
Ki-67 LI 
(%)†
37.4 
± 21.7
46.2 
± 23.8
N.S. 
(0.057)
46.0 
± 24.4
36.4 
± 21.4
N.S. 
(0.069)
46.9 
± 23.7
29.8 
± 20.0
0.001*
44.9 
± 24.3
32.0 
± 4.5 N.S.
*Statistically significant (P < 0.05); †mean ± SD
Abbreviations: LI = labeling index; WT = wild type; Mut = mutation; Neg = negative; Pos = positive; N.S. = not significant.
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SDCs showed poorer PFS in comparison to those 
with carried wild-type TP53 (P = 0.017); however, 
the difference was not statistically significant in the 
multivariate analysis. Furthermore, the presence 
of a TP53 truncating mutation was a significant 
independent predictor of poor PFS in both the 
univariate and multivariate analyses (P = 0.008 and 
0.004, respectively). While, p-Akt-positive expression 
was associated with a favorable clinical outcome 
indicated by better OS and PFS in a univariate analysis 
(P = 0.017 and 0.023, respectively); these associations 
showed marginal trend in the multivariate analysis (P 
= 0.064 and 0.106, respectively).  
Kaplan-Meier survival curves indicated that 
patients with TP53 mutated SDC showed worse OS 
and PFS (P = 0.060 [marginal significance] and 
0.015, respectively) than SDC patients with wild-type 
TP53; furthermore, TP53 truncating mutations were 
significantly associated with poorest PFS (P = 0.026) 
(Figure 5). In the HER2-negative subgroup, a TP53 
mutation was an indicator of worse OS and PFS (P 
= 0.041 and 0.013, respectively). In contrast, p-Akt 
positivity was associated with higher OS and PFS (P 
= 0.013 and 0.018, respectively) (Figure 6). The other 
molecular and immunohistochemical factors that were 
examined showed no association with the survival 
rates.
DISCUSSION
SDC has a very poor prognosis and the treatment 
options are limited [1–5]. We performed extensive 
molecular and immunohistochemical analyses of genes 
and biological markers either related to the driving 
tumorigenesis and/or relevant treatment targets in 151 
cases of SDC. In patients with SDC, the most frequent 
gene alterations were observed in TP53, followed by 
PIK3CA, H-RAS, BRAF, and AKT1; this finding was in 
agreement with previous comprehensive genetic studies 
[9–17]. However, there is little in the way of convincing 
data in relation to the clinicopathological and prognostic 
implications of these molecular changes, mostly due 
to the rarity of SDC. Thus, the present study, which 
includes a large cohort of SDC patients, provides results 
that can more reliably interpret the associations between 
the mutation/expression status and clinicopathological 
features, including histogenesis and the clinical outcome. 
First, we found that PIK3CA/H-RAS/BRAF mutations 
were preferentially identified in de novo SDCs but not in 
SDCs ex-PA. These mutations and HER2 overexpression/
amplification were mutually exclusive. Second, TP53 
mutations were common events in SDC, and the 
truncating form of the given gene was independently 
associated with a worse prognosis. Additionally, TP53 
mutations were frequently detected in cases with an 
extreme p53-negative/positive immunophenotype, and 
Figure 1: Examples of the direct DNA sequencing analysis. (A) TP53 missense mutation (R175H). (B) TP53 frameshift mutation 
(P152fs*18). (C) PIK3CA mutation (H1047R). (D) H-RAS mutation (Q61R). (E) BRAF mutation (V600E).
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TP53 missense and truncating mutations were associated 
with extreme p53 positivity and negativity, respectively. 
Finally, we demonstrated that at least one-fifth of SDC 
cases aberrantly expressed PI3K/Akt signaling pathway 
proteins, along with a mutual correlation with the 
expression profile according to the axis. Furthermore, we 
revealed that p-Akt positivity indicates a favorable clinical 
outcome. Moreover, PI3K negativity and PTEN loss were 
associated with low AR expression. We believe that in the 
future these data will be important in the implementation 
of personalized therapy for SDC.
SDC can occur as a de novo tumor, and can develop 
through malignant transformation from PA. It has been 
shown that the survival of patients with SDC ex-PA and 
those with de novo SDC does not differ to a statistically 
significant extent [20, 21]. Recently, studies analyzing 
small cohorts have shown that the underlying molecular 
mechanism and therapeutically-relevant genetic alterations 
in SDC might differ between de novo and ex-PA (Table 
5) [13, 14, 18, 19]. However, conflicting results have 
been reported [13, 14, 18]. Chiosea et al. examined 39 
cases and found that PIK3CA and H-RAS mutations were 
predominantly detected in de novo SDCs, whereas TP53 
mutations and ERBB2 amplification were more commonly 
observed in SDCs ex-PA [13]. They investigated the 
presence of pre-existing PA based on a combination 
of histomorphology and the PLAG1 and HMGA2 
rearrangement status. On the other hand, Griffith et al. failed 
to find an association between the PIK3CA status and the 
histologic origin in their analysis of 34 cases [18]. In the 
study of 43 cases, Grünewald et al. demonstrated that the 
TP53 mutation rate was not influenced—to a statistically 
significant extent—by the histologic origin [14]. Our 
current analysis of much larger series of patients with 
SDC revealed hot spot mutations of PIK3CA and H-RAS 
in 18.2% and 16.2% of the cases, respectively, and showed 
the intimate relationship between the presence of PIK3CA 
mutations, frequently accompanied by simultaneous 
H-RAS mutations, and de novo occurrence. Although these 
findings confirm the data presented by Chiosea et al. [13], 
we identified cases of SDC ex-PA by a histomorphological 
evaluation using multi-step sections from the whole 
tumor. We found no significant association between the 
histological origin and the expression of PI3K, p-Akt, 
p-mTOR, and PTEN. Moreover, in agreement with the 
results presented by Grünewald et al., the TP53 mutation 
rate did not differ according to the histologic origin [14]. 
Conversely, although the mutation rate was low, BRAF 
mutations (V600E)—one of the major therapeutic targets 
[22]—were only detected in de novo SDCs. Furthermore, 
our data showed that PIK3CA/H-RAS/BRAF mutations and 
HER2 positivity are mutually exclusive, and that SDCs ex-
PA more frequently overexpressed HER family members, 
including HER2 (and/or HER2 amplification), EGFR, 
and HER3 [19]. These findings indicate that PIK3CA and 
H-RAS mutations in de novo SDCs and the disruption of the 
HER family members in SDCs ex-PA may play crucial roles 
in their carcinogenesis. These insights should be considered 
when designing clinical trials and when planning potential 
targeted therapeutic strategies against SDCs based on the 
histological origin. Instead, consistent with previous studies, 
these molecular changes were not correlated with the 
patient outcome [8, 9, 18, 19]. The further clarification of 
the mechanisms associated with the development of SDCs 
is expected to lead to novel targeted therapies. 
TP53 is well known to be the most frequently 
mutated gene in human malignancies; mutations are found 
in at least 50% of human cancers [23–25]. In the current 
study, TP53 mutations were found in 68% of the SDC 
cases, which is in line with previous reports [9, 13, 15, 
16]. Pathogenic mutations result in the loss or abrogation 
of wild-type p53 activity and the dominant-negative 
effect on the remaining wild-type p53, in addition some 
p53 mutants often gain oncogenic functions to promote 
tumorigenesis and progression [26]. Given the broad 
role of p53 in malignancy, there is an intense focus on 
its potential as a therapeutic target [27, 28]. Furthermore, 
TP53 mutations have been shown to be an independent 
marker of a poor prognosis in cancers of several organs 
[23–25]. Meanwhile, it should be noted that the prognostic 
Table 3: Correlation between p53-expression phenotype and TP53 status 
p53-expression phenotype n
TP53 status
Wild type
Mutation
Missense Truncating
 Non-extreme 71 31*
40*
21 19
 EN + EP 53 9* 44*
 EN 18 3 5† 10†
 EP 35 6 26† 3†
Total 124 40 84
*P = 0.002; †P < 0.001
Abbreviations: EN = extreme negative; EP = extreme positive.
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significance of TP53 mutations shows extreme variation 
according to the type of tumor [23–25]. In SDCs, it is not 
clear whether TP53 mutation independently predicts a 
poor prognosis. Most recently, Grünewald et al. reported 
that TP53 mutated SDCs tended to be associated with a 
worse OS; however, the result did not reach statistical 
significance due to the relatively small number of 
patients [14]. In the present study, TP53 mutations were 
significantly associated with a poor PFS in a univariate 
analysis, but not in the multivariate analysis. A subgroup 
analysis using Kaplan-Meier survival curves showed 
that TP53 mutations were associated with worse OS and 
PFS in HER2-negative patients. In general (not limited 
to SDCs) major TP53 mutations are missense and cause 
single amino-acid changes at many different positions 
[23–25]. The mutations, however, are diverse in their type, 
sequence context, and structural impact—these differences 
influence the biological behavior of various cancers 
[23–25]. Missense substitutions, particularly certain “hot 
spots” mutations, have been shown to induce loss of DNA 
binding activity, transactivation capacity, and dominant-
negative effects, as well as gain-of-function (GOF) 
properties, including altered cancer spectrum, deregulated 
metabolic pathways, increased metastasis and enhanced 
chemotherapy resistance [28–30]. Conversely, truncating 
TP53 mutations, such as frameshift insertions and deletions 
and nonsense mutations, correspond to loss-of-function 
(LOF) TP53 mutations and are thought to give rise to 
p53-null alleles [31–33]. In ovarian carcinomas, it has 
been suggested that distinguishing between GOF and LOF 
TP53 mutations is clinically important as LOF mutations 
have been associated with worst prognosis in comparison 
to GOF mutations and wild-type [34, 35]. We found that 
in SDCs the rates of wild-type, missense mutation, and 
truncating mutation were 32%, 42%, and 26% of the cases, 
respectively. Thus, by dividing TP53 status into 3 types 
(wild-type, missense mutations, and truncating mutations), 
we—for the first time—demonstrated that truncating 
mutations were a strongly independent adverse prognostic 
factor in SDC. Although mutations out of ‘‘hot spots’’ or 
large deletions/insertions might have been missed in our 
study, the molecular signatures of TP53 are very useful for 
determining therapeutic strategies. 
The p53 expression (which is determined by 
immunohistochemistry) is widely used as a surrogate 
marker of TP53 mutation status; however, its reliability 
has not been established in SDCs. It has been generally 
accepted that wild-type p53 protein is relatively unstable 
and has a short half-life, which makes it undetectable 
by immunohistochemistry, whereas mutant p53 has a 
much longer half-life, and therefore accumulates in the 
nucleus creating a stable target for immunohistochemical 
detection [30]. However, the overexpression of wild-type 
p53 can sometimes occur due to impaired degradation 
under cellular stress [30]. On the other hand, truncating 
mutations invariably lead to the disruption of protein 
synthesis, and the biological consequences might differ 
from those of missense mutations [33]. In the present 
study of SDCs—as has been demostrated in breast [36] 
and ovarian carcinomas [37–39]—we proved that extreme 
p53 positivity and negativity was associated with TP53 
missense and truncating mutations, respectively; this 
possibility has been suggested previously [11, 14]. This 
could provide a reasonable explanation of why extreme 
p53 positivity/negativity was associated with a worse 
prognosis in SDCs, as was shown our recent study [19]. 
It should be noted that the absence of protein expression 
tends to confound the interpretation of immunostaining, 
leading to false-negative results, especially in the case of 
truncating mutations.
The PI3K/Akt pathway is central in the regulation 
of multiple cancer-relevant regulatory processes that 
affect cell survival, cell growth, and cell cycle progression 
[40–42]. PI3K and its downstream components (including 
Figure 2: Dual color in situ hybridization for the EGFR gene. (A) No abnormalities. (B) The presence of chromosome 7 
polysomy but no EGFR gene amplification (HER2 genes: black signal, CEN 17: red signal).
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Akt and mTOR) in turn cross-talk with a number of other 
pathways, thereby leading to a complex network of signals; 
the disruption of which may have dramatic consequences 
[40–42]. In addition, PTEN is a major negative regulator 
of the PI3K activity [40, 43, 44]. The deregulation of the 
PI3K/Akt pathway—including activation and somatic 
mutations—in this pathway is frequently found in various 
cancers; thus it represents an attractive target for therapy 
[40–42, 45, 46]. Aberrations in this pathway have also 
recently been implicated in salivary gland tumorigenesis 
[13, 18, 47–49]. We disclosed that the overexpression 
of PI3K, activated Akt (p-Akt), and activated mTOR 
(p-mTOR), and the loss of PTEN are common in SDC. 
Furthermore, PTEN loss was negatively and positively 
correlated to PI3K expression and its downstream 
p-Akt nuclear expression, respectively. Moreover, a
positive correlation was found between the expression 
of p-Akt and the downstream expression of p-mTOR. 
These observations indicate that activation of the PI3K/
Akt pathway through the axis plays a crucial role in the 
pathogenesis of a subset of SDCs. On the other hand, we 
have shown that PIK3CA mutations are not associated with 
the high expression of downstream-activated proteins; this 
finding is in line with other cancer studies [50, 51].
The correlation between the expression of the PI3K/
Akt signaling pathway proteins and the clinical outcome of 
salivary gland carcinomas has not been fully clarified. To the 
best of our knowledge, this is the first study to report that 
p-Akt negativity is associated with an unfavorable prognosis 
in patients with SDC; however, similar findings have been 
described in relation to salivary adenoid cystic carcinoma 
[48] and “high-grade tumors,” without focusing on sub-
entities such as SDC [47]. In the current study, the expression
of PI3K, PTEN, and p-mTOR had no impact on the survival
of SDC patients. Furthermore, we could not demonstrate any
significant association between the PIK3CA status and the
clinical outcome, even though wild-type PIK3CA tumors
showed higher proliferation index values. Similar findings
have been reported in breast cancer patients [51, 52].
It is well known that SDC demonstrates the high 
expression of AR, as was shown in our results [19]. Thus, 
AR has been the target of androgen deprivation therapy 
(ADT) for SDC in recent years [4, 5], similarly to prostate 
cancer [53]. The PI3K/Akt pathway is important in both 
androgen-sensitive and hormone-refractory prostate 
cancer, with functional cross-talk between the pathway 
and the AR activity involved in both the initiation and 
progression of prostate cancer [54–57]. Interestingly, 
Table 4: Interrelation between the mutation and expression of molecules associated with the PI3K/
Akt signaling pathway in salivary duct carcinomas
PI3K PTEN p-Akt p-Akt (N) mTOR
Neg Pos P Loss Intact P Neg Pos P Neg Pos P Neg Pos P
PIK3CA – – – – – – – – – – – – – – –
   WT 72 39
N.S.
58 53
N.S.
87 23
N.S.
96 14
N.S.
39 72
N.S.
   Mut 17 8 9 16 18 7 19 6 6 19
– – – – – – – – – – – – – – –
PI3K – – – – – – – – – – – – – – –
   Neg – – – 56 42
0.006*
78 19
N.S.
86 11
N.S.
36 62
N.S.
   Pos – – – 17 34 37 13 40 10 15 36
– – – – – – – – – – – – – – –
PTEN – – – – – – – – – – – – – – –
   Loss – – – – – – 52 20 N.S. 
(0.084)
56 16
0.007*
30 43 N.S. 
(0.083)   Intact – – – – – – 63 12 70 5 21 55
– – – – – – – – – – – – – – –
p-Akt – – – – – – – – – – – – – – –
Neg – – – – – – – – – – –
–
45 70
0.032*
Pos – – – – – – – – – – – 6 26
– – – – – – – – – – – – – – –
p-Akt (N) – – – – – – – – – – – – – – –
Neg – – – – – – – – – – – – 48 78
0.034*
Pos – – – – – – – – – – – – 3 18
*Statistically significant (P < 0.05)  Abbreviations: p-Akt (N) = p-Akt nuclear expression; WT = wild type; Mut = mutation; Neg = negative; Pos =
positive; N.S. = not significant.
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Figure 3: Immunohistochemical staining of the PI3K/Akt signaling pathway. (A) PI3K. Diffuse cytoplasmic staining. (B) 
p-Akt. Half of the tumor cells show both nuclear and cytoplasmic staining. (C) p-mTOR. Many tumor cells are positive with cytoplasmic
and membranous staining pattern. (D) PTEN. Expression loss. Note that the expression of stromal  and adjacent salivary gland parenchymal 
cells is retained.
Table 5: Association between the histologic origin and therapeutically-relevant genetic alterations 
in salivary duct carcinomas
Histologic origin
TP53 PIK3CA H-RAS BRAF HER2* (ERBB2†)
WT Mut P WT Mut P WT Mut P WT Mut P Neg Pos P
Current study
   De novo 20 29
N.S.
35 18
< 0.001‡
35 19
< 0.001‡
46 5
0.004‡
43 14
< 0.001‡
   Ex-PA 19 52 72 7 77 4 80 0 35 54
Griffith et al. (2013) (Ref. 18)
   De novo
N.A.
14 5
N.S. N.A. N.A. N.A.
   Ex-PA 12 2
Grünewald et al. (2016) (Ref. 14)
   De novo 14 18
N.S. N.A. N.A. N.A. N.A.
   Ex-PA 4 7
Chiosea et al. (2016) (Ref. 13)
   De novo 7 1
0.033‡
2 6
0.010‡
3 5
0.029‡
8 0
N.S.
8 0
0.005‡
   Ex-PA 14 17 23 8 24 7 29 2 14 17
*HER2 status was assessed by a combination of immunohistochemistry and FISH analysis in accordance with the 2013 ASCO/CAP guideline. (Data from our previous report [Ref. 19])
†ERBB2 positive was defined as > 8 genes gain by next-generation sequencing (Ref. 13).
‡Statistically significant (P < 0.05)
Abbreviations: PA = pleomorphic adenoma; WT = wild type; Mut = mutation; Neg = negative; Pos = positive; N.S. = not significant; N.A. = not available.
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we found that PI3K negativity and PTEN loss were 
significantly correlated with the lower expression of 
AR in SDC. This study may provide novel evidence 
demonstrating interaction between the PI3K/Akt and 
AR pathways in SDC, and may be the first step toward 
elucidating the mechanisms of ADT therapy.
In conclusion, the present study, which included the 
largest series of patients with SDC, confirms the molecular 
variability and heterogeneity of treatment-relevant targets 
in this tumor. Our data shows that the genetic mechanisms 
underlying carcinogenesis differ according to the 
histogenesis and highlight the importance of subclassifying 
SDC based on specific molecular abnormalities. Almost 
all gene mutations in TP53, PIK3CA, H-RAS, BRAF, and 
AKT1 that were identified in this study were covered by 
the Catalogue of Somatic Mutations in Cancer (COSMIC), 
and most of these mutations are oncogenic, for which a 
functional analysis has already been performed [58–62]. 
However, an integrated molecular evaluation, including 
whole-exome sequencing, transcriptome and proteome 
analyses, and in vitro cell culture and patient-derived 
xenograft experiments, is warranted for gaining a greater 
understanding of the pathogenesis of this high-grade 
salivary gland carcinoma and the activity of targeted 
therapies. Besides, our analysis suggests that TP53 
truncating mutations, which are correlated with p53-
extreme negative expression, is an adverse prognostic 
factor in SDC. Additionally, the activation of the PI3K/
Akt pathway with interaction with AR, which shows some 
prognostic impact in SDC, implies that it has the potential 
Table 6: Univariate and multivariate analysis of clinical outcomes in patients with salivary duct 
carcinoma
Molecules
Overall survival Progression-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
n HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
TP53
WT 40 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Mut 85 1.81 0.97-3.37 N.S. (0.062) 1.56 0.82-2.97 N.S. 1.82 1.11-2.99 0.017
* 1.45 0.87-2.44 N.S.
WT 40 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Missense 52 1.94 1.00-3.75 0.049* 1.45 0.73-2.85 N.S. 1.64 0.97-2.79 N.S. (0.067) 1.13 0.64-1.98 N.S.
Truncating 33 1.60 0.76-3.37 N.S. 1.88 0.84-4.21 N.S. 2.19 1.23-3.90 0.008* 2.54 1.35-4.76 0.004*
PIK3CA
WT 112 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Mut 25 0.75 0.38-1.46 N.S. 0.63 0.29-1.36 N.S. 0.77 0.45-1.32 N.S. 0.71 0.39-1.28 N.S.
H-RAS
WT 117 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Mut 23 0.69 0.36-1.35 N.S. 0.77 0.35-1.67 N.S. 0.77 0.44-1.33 N.S. 1.03 0.54-1.94 N.S.
BRAF
WT 131 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Mut 5 0.37 0.05-2.65 N.S. 0.27 0.03-2.09 N.S. 0.40 0.10-1.62 N.S. 0.36 0.08-1.55 N.S.
Chromosome 7 polysomy
Absent 113 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Present 19 0.66 0.27-1.66 N.S. 0.37 0.14-0.96 0.040* 1.25 0.69-2.25 N.S. 0.90 0.49-1.65 N.S.
PI3K
Neg 98 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Pos 51 0.65 0.38-1.13 N.S. 0.74 0.41-1.36 N.S. 1.01 0.68-1.52 N.S. 1.26 0.80-1.98 N.S.
p-Akt
Neg 115 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Pos 32 0.44 0.22-0.86 0.017* 0.50 0.24-1.04 N.S. (0.064) 0.54 0.32-0.92 0.023
* 0.62 0.35-1.11 N.S. (0.106)
p-mTOR
Neg 51 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Pos 98 0.96 0.59-1.55 N.S. 1.42 0.83-2.44 N.S. 0.79 0.53-1.17 N.S. 1.02 0.65-1.60 N.S.
PTEN
Loss 73 1.00 - - 1.00 - - 1.00 - - 1.00 - -
Intact 76 1.08 0.67-1.74 N.S. 1.04 0.61-1.76 N.S. 0.98 0.67-1.44 N.S. 1.00 0.65-1.55 N.S.
Adjusted by age, sex, primary site, TNM clasification, definitive treatment, and histologic origin.
*Statistically significant (P < 0.05)
Abbreviations: HR = hazard ratio; CI = confidence interval; WT = wild type; Mut = mutation; Neg = negative; Pos = positive; N.S. = not significant.
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to be a biomarker of tumor aggressiveness, which may be 
useful for selecting hormonal and targeted therapy. Further 
validation in clinical trials would be expected for the 
development of therapy selection and treatment strategy 
in patients with SDC.
MATERIALS AND METHODS
Patients and tissue specimens
The present multicenter collaborative retrospective 
study was approved by the Institutional Review Board of 
each facility. 
In total, 151 SDC patients were diagnosed and 
treated at 7 institutions between 1992 and 2014. Patients 
who underwent anti-HER2 or anti-AR therapy as an initial 
treatment were excluded. These patients included cases that 
were previously reported by our collaborative facilities [2, 
19, 63]. All of the cases in the central review system were 
correctly diagnosed by an expert pathologist (T.N.) based on 
strict histological criteria in accordance with the 2017 WHO 
Classification of Tumors [1]. In principle, multi-step sections 
from the whole tumor were subjected to a histological 
review. Cases were considered to be SDC ex-PA when a 
pre-existing PA component was histologically detected 
in the tumor, even if it was represented by a markedly 
hyalinized nodule. On the other hand, in cases where no PA 
component was identified in any of the sections examined, 
the tumor was diagnosed as de novo SDC. When only biopsy 
samples were available for examination, the histologic origin 
was categorized as “unknown” (n = 5). Tumor stage was 
determined according to the UICC TNM classification and 
staging system (2009, 7th edition). Clinical information was 
collected from the patients’ medical records by the person-
in-charge in each facility. 
Mutational analysis
With microdissection methods, DNA of the 
carcinoma cell-rich part in each case was carefully 
extracted from the paraffin-embedded thin-sliced 
sections using a QIAmp DNA FFPE Tissue Kit 
(QIAGEN GmgH, Hilden, Germany), purified using 
QIAquick Spin Kit (QIAGEN GmgH), and subjected 
to a purity check using Nano Drop (Thermo Fisher 
Scientific, MA). A gene alteration analysis was 
performed for TP53 (exons 4–10), PIK3CA (exons 9 
and 20), AKT1 (exon 2), K-RAS (exons 1-2), N-RAS 
(exons 1-2), H-RAS (exons 1-2), and BRAF (exon 15) by 
Sanger sequencing. The primer sequences are described 
in Supplementary Table 3.
DISH
The EGFR gene copy number was assessed by 
a DISH analysis using Benchmark ULTRA (Ventana 
Medical Systems, CA); staining was performed according 
to the manufacturer’s protocol (Roche, Basel Switzerland). 
Briefly, 20 tumor cells in which both EGFR signaling 
(black signal) and chromosome 7 centromere (CEN7) (red 
signal) were depicted and counted to calculate the ratio 
of the total number of EGFR signals to the total number 
of CEN7 signals. An EGFR/CEN7 ratio of ≥2.0 was 
considered to indicate EGFR gene amplification, whereas 
a mean CEN7 signal number of ≥3.0/cell was considered 
to indicate the presence of chromosome 7 polysomy. 
Figure 4: The comparison of androgen receptor labeling index (AR LI) with PI3K/PTEN expression. PI3K negativity (A) 
and PTEN loss (B) are significantly associated with lower AR LI (PI3K: mean [%] ± SD, 47.6 ± 34.5 versus 66.2  ±  29.6; PTEN: 42.7 ± 34.8 
versus 64.7  ±  29.6).
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Figure 6: The Kaplan-Meier survival curves for patients with salivary duct carcinoma stratified by the p-Akt 
expression status. Both overall survival (A) and progression-free survival (B) were significantly worse in p-Akt-negative patients than 
in p-Akt-positive patients.
Figure 5: Kaplan-Meier survival curves of patients with salivary duct carcinoma stratified by their TP53 status. (A) 
TP53 mutated patients tended to show poorer overall survival (OS) than TP53 wild-type patients, with marginal significance. (B) The 
progression-free survival (PFS) of the TP53 mutated patients was significantly worse than that of the TP53 wild-type patients. (C) The OS 
of patients with TP53 wild-type, missense mutations, and truncating mutations tended to decrease in this order. (D) The PFS of patients with 
TP53 truncating mutations was significantly worst, followed in order by missense mutations and wild-type.
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Immunohistochemistry
Immunohistochemical staining was performed 
for PI3K, p-Akt, p-mTOR, and PTEN using 4-μm-thick 
formalin-fixed, paraffin-embedded tissue sections. The 
antibodies used in the assay are shown in Supplementary 
Table 4. The cases were regarded as positive for PI3K, 
p-Akt, and p-mTOR when the percentage of cytoplasmic 
and/or nuclear staining cells was >10%. With regard to 
p-Akt, nuclear positivity was indicated as “p-Akt (N)”. 
The PTEN expression level was scored semiquantitatively, 
as described previously [64]. The normal surrounding 
epithelium served as an internal control. Tumor tissues 
were scored as follows: score 2, same staining intensity as 
that of the normal epithelium; score 1, staining intensity 
weaker than normal; score 0, no staining. We considered 
scores of 0 and 1 to indicate a loss of PTEN.
Statistical analysis
The chi-squared test and Mann-Whitney U test were 
used to compare non-continuous and continuous variables, 
respectively. Univariate and multivariate Cox proportional 
hazards models and the Kaplan-Meier product-limit 
method were used to investigate the associations between 
the molecular/immunohistochemical results and OS 
and PFS. The potential confounders in the multivariate 
analysis included age, gender, TNM classification, 
primary site, first-line treatment, and histologic origin 
(de novo vs. SDC ex-PA). The strength of an association 
was determined by the hazard ratio and the 95% CI. The 
statistical analyses were performed using the STATA 
software program (version 13, StataCorp., College Station, 
TX). All of the tests were two-sided, and P values of < 
0.05 were considered to indicate statistical significance.
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